SAHPRA: South Africa's Trial Approval Pathway

South Africa regulates clinical trials and bioequivalence studies through a single national authority, the South African Health Products Regulatory Authority (SAHPRA), working alongside independently registered Research Ethics Committees (RECs). SAHPRA was established under the Medicines and Related Substances Amendment Act 14 of 2015, which came into force in 2017 and replaced the former Medicines Control Council (MCC) with a standalone regulatory authority operating as an organ of state outside the public service. For sponsors and CROs planning a multi-country trial, or for a generics manufacturer evaluating South Africa as a bioequivalence-study site, understanding SAHPRA’s Clinical Trial Unit, its statutory basis, and its realistic timelines is the starting point.

SAHPRA’s Role and Structure

SAHPRA is the national regulator responsible for the monitoring, evaluation, regulation, investigation, inspection, registration, and control of medicines, scheduled substances, medical devices, radiation-emitting devices, and clinical trials in South Africa. It is governed by a Board of roughly 10-15 members with expertise spanning medicine, medical devices, in-vitro diagnostics, pharmacovigilance, clinical trials, good manufacturing practice, public health, law, and finance.

Within SAHPRA, the Clinical Trial Unit is the specific operational unit responsible for clinical trial and bioequivalence-study oversight: it receives, processes, and evaluates applications from researchers, sponsors, and industry to conduct studies in South Africa, and it authorizes the importation of unregistered investigational medicines for trial purposes. This is a materially different structure from jurisdictions that split trial authorization and generic-drug bioequivalence review across separate offices — in South Africa, the same Clinical Trial Unit within SAHPRA handles both.

Legal Framework

The governing statute is the Medicines and Related Substances Act, Act 101 of 1965, as amended. Section 21 of the Act is the specific provision that permits SAHPRA to authorize the sale, use, or administration of an unregistered medicine for the purposes of a clinical trial — it is the legal mechanism under which every investigational product enters a South African trial. The Medicines and Related Substances Amendment Act 14 of 2015 is the enabling legislation that created SAHPRA itself, replacing the MCC and also bringing medical devices and IVDs into the same regulatory authority’s scope.

Layered on top of the statute, SAHPRA publishes the South African Good Clinical Practice (SA GCP) Guidelines, now in a revised edition, which set the operational standard researchers and sponsors must follow for trial conduct, informed consent, safety reporting, and site-level quality — comparable in function to the ICH E6 Good Clinical Practice guideline referenced throughout CASRAI’s Good Clinical Practice coverage, though SA GCP is South Africa’s own document with its own specific requirements.

The Clinical Trial Application (CTA) Process

SAHPRA’s Clinical Trial Unit runs applications on a submission-cycle model rather than accepting them on a rolling basis at all times: applications must be submitted on predetermined dates published by SAHPRA, accompanied by proof of delivery, payment confirmation for the prescribed fee, and a cover page, generally submitted by email alongside the formal application. Sponsors should confirm the current submission-date calendar directly on sahpra.org.za before planning a filing, since predetermined-date systems shift periodically.

Published processing timelines from SAHPRA’s Clinical Trial Unit are:

Initial checklist: issued within approximately 3 weeks of receipt, confirming the application is administratively complete enough to proceed to substantive review.
Clinical Trial Committee (CTC) recommendation: targeted within approximately 10 weeks of the relevant submission due date.
Protocol amendments and additional investigator/site requests: targeted at approximately 6 weeks.

SAHPRA notes that these timelines can extend where an application requires external reviewer input or referral to another SAHPRA committee — the same pattern seen in other jurisdictions’ regulatory review, such as the Subject Expert Committee routing described in CASRAI’s CDSCO (India) clinical trial approval guide. As with any published regulatory timeline, treat these figures as targets rather than guarantees, and build contingency into a country-level project plan rather than assuming the fastest-case figure.

Research Ethics Committee (REC) Requirements

A South African clinical trial needs both SAHPRA’s Section 21 authorization and a favourable opinion from a registered Research Ethics Committee (REC) before enrolment — neither is sufficient on its own. RECs reviewing health research in South Africa, including clinical trials and bioequivalence studies, are registered under South Africa’s National Health Act framework, with the National Health Research Ethics Council (NHREC) responsible for registering and setting standards for RECs nationally. Sponsors should confirm that the specific site-level REC they intend to use holds current, valid registration before submitting a protocol to it.

SAHPRA’s SA GCP Guidelines require investigators and site staff involved in a trial to hold documented proof of Good Clinical Practice training — this is a standing expectation for anyone in an investigator role on a South African trial, not a one-time historical certification, and sponsors conducting site-readiness assessments should verify current GCP training records as part of site selection.

Bioequivalence Study Authorization

Because South Africa’s generic-medicine approval pathway depends on demonstrating bioequivalence to a reference product, SAHPRA’s Clinical Trial Unit also authorizes bioequivalence (BE) studies through the same Section 21 mechanism used for therapeutic clinical trials, with a dedicated point of contact for bioequivalence protocol queries. This matters specifically for generics manufacturers and contract research organizations running BE studies as part of a multisource (generic) medicine registration dossier: the BE study itself needs SAHPRA authorization before it can proceed in South Africa, on broadly the same submission-cycle and Clinical Trial Unit review process described above for therapeutic trials, even though the study’s ultimate purpose (supporting a generic registration) differs from a therapeutic efficacy trial.

SAHPRA has also published reliance-guideline material addressing how it applies reliance on other regulators’ decisions separately for quality-and-bioequivalence review versus clinical evaluation — a distinction worth understanding for sponsors hoping to leverage a bioequivalence assessment already completed by another stringent regulatory authority rather than repeating the full review in South Africa from scratch. Confirm the current reliance framework directly against SAHPRA’s published reliance guideline before assuming any specific foreign assessment will be accepted.

Post-Approval Obligations

Section 21 authorization is not a one-time event with no further reporting obligation. Sponsors should expect ongoing obligations for the life of the trial, including adverse event and safety reporting consistent with SA GCP, and a final study report submitted to SAHPRA within a defined window after study completion — sponsors should confirm the current reporting deadline directly against SAHPRA’s own published requirements at the time of trial closeout, since post-trial reporting windows are exactly the kind of administrative detail that shifts between guideline revisions.

Common Pitfalls for International Sponsors

Missing a submission date. Because SAHPRA’s Clinical Trial Unit reviews on predetermined submission dates rather than accepting applications continuously, missing a cycle can add weeks to a timeline that a rolling-submission system would not impose.
Treating SAHPRA authorization and REC approval as sequential rather than parallel tracks. As in several other jurisdictions CASRAI covers in this series, running the two reviews in parallel rather than waiting for one to clear before starting the other is generally the more time-efficient approach.
Assuming a stringent-regulatory-authority approval elsewhere automatically transfers. SAHPRA’s reliance pathways are a real mechanism but apply on defined terms, separately for quality/bioequivalence versus clinical evaluation — confirm eligibility rather than assuming reliance applies.
Underestimating GCP-training documentation requirements for investigators. Site-readiness reviews that skip verifying current, documented GCP training for all listed investigators risk a query cycle that a complete initial submission would have avoided.
Conflating bioequivalence-study authorization with the separate generic-medicine registration dossier it supports. BE study authorization from the Clinical Trial Unit is a distinct step from the multisource medicine registration application itself.

How South Africa Compares to Other Jurisdictions

SAHPRA’s model — a single national authority (via its Clinical Trial Unit) handling both therapeutic clinical trial and bioequivalence-study authorization under one statutory mechanism (Section 21), paired with independently registered RECs — sits alongside the other national pathways CASRAI covers in this series: the dual-track regulator/ethics-body split in Brazil under ANVISA, India’s single-regulator-plus-registered-Ethics-Committee model under CDSCO, China’s NMPA process, South Korea’s MFDS pathway, and the framework compared in CASRAI’s EMA vs. FDA guide. Across all of these, the same underlying principle holds, consistent with the ICH Good Clinical Practice framework: a trial needs both a competent-authority authorization and an independent ethics opinion before enrolment can begin, and country-specific submission-cycle and timeline mechanics need to be built into a multi-country trial plan individually rather than assumed to transfer from one jurisdiction to another.

Frequently Asked Questions

What authorizes a clinical trial to proceed in South Africa?

Two things, both required: SAHPRA’s Section 21 authorization (under the Medicines and Related Substances Act, 1965) for the investigational medicine, and a favourable opinion from a registered Research Ethics Committee (REC) for the protocol. Neither alone is sufficient to enrol participants.

How long does SAHPRA take to approve a clinical trial application?

SAHPRA’s Clinical Trial Unit targets issuing an initial checklist within about 3 weeks of receipt and a Clinical Trial Committee recommendation within about 10 weeks of the relevant submission due date, with protocol amendments targeted at around 6 weeks. These are published targets, not guarantees, and can extend where external reviewer or committee referral is needed.

Does SAHPRA authorize bioequivalence studies as well as therapeutic trials?

Yes. SAHPRA’s Clinical Trial Unit authorizes bioequivalence (BE) studies for generic/multisource medicines through the same Section 21 mechanism used for therapeutic clinical trials, and maintains a dedicated contact point for bioequivalence protocol queries.

What replaced the Medicines Control Council (MCC) in South Africa?

SAHPRA did. The Medicines and Related Substances Amendment Act 14 of 2015 established SAHPRA as a standalone regulatory authority, which came into force in 2017 and took over the MCC’s functions along with expanded scope covering medical devices and IVDs.

Who registers Research Ethics Committees in South Africa?

Research Ethics Committees reviewing health research, including clinical trials and bioequivalence studies, operate under South Africa’s National Health Act framework, with the National Health Research Ethics Council (NHREC) responsible for registering and setting standards for RECs nationally. Confirm any specific REC’s current registration status before submitting a protocol to it.

Can a foreign regulator’s bioequivalence approval be relied on for a South African submission?

SAHPRA has published reliance-guideline material that applies reliance separately for quality/bioequivalence review and for clinical evaluation, under defined conditions — it is a real mechanism but not an automatic transfer. Confirm current eligibility criteria directly against SAHPRA’s published reliance guideline before assuming a specific foreign assessment will be accepted.

Related CASRAI Resources

Sourced from SAHPRA’s own published pages and guidance at sahpra.org.za (Clinical Trials Unit page, SA GCP Guidelines, reliance guideline, and the Medicines and Related Substances Act 101 of 1965 as amended), cross-checked against secondary regulatory-affairs commentary, as of this guide’s publication date. Submission dates, fees, and timelines change periodically — always confirm current requirements directly on sahpra.org.za before finalising a country-level project plan.